Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor overview
Stock information
Press releases
Events
SEC filings
Corporate governance
Investor presentations
Investor FAQs
Email alerts

Investor contact

For investor related questions, please email

investors@aclaristx.com

Media contact
& resources »

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

October 20, 2020

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

September 1, 2020

Aclaris Therapeutics to Present at Upcoming Investor Conferences

August 7, 2020

Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights

Events

Sep 17, 2020
10:40 AM EDT

Aclaris Therapeutics, Inc. at Cantor Virtual Global Healthcare Conference

Sep 15, 2020
12:30 PM EDT

Aclaris Therapeutics, Inc. at H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Jun 17, 2020
8:30 AM EDT

Aclaris Therapeutics Announces Investigator-Initiated Trial of ATI-450 for CRS in Hospitalized Patients with COVID-19

Feature presentation

More presentations coming soon.

Aclaris - Footer Menu

Terms of use
Privacy policy
Media resources
Contact us

© 2020 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.